Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Combatting Antimicrobi...
Provisional Deal Ushers in EU Pharmaceutical Reform
The European Parliament and Council have reached a provisional agreement to overhaul the EU's pharmaceutical policy framework, marking a major step in the EU Pharmaceutical Refor...
AI Governance Pharmaceuticals: Ensuring Ethical AI Integration in the Medicines Lifecycle
In the pharmaceutical industry, AI governance in pharmaceuticals is crucial for harnessing artificial intelligence's potential in drug discovery, clinical trials, and patient monitoring. How can pharma companies integrate AI ethically across the medicines lifecycle? This article draws on a recent...
2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solutions
Expansion of Coverage in the 2025 National Basic Medical Insurance Drug Catalog
In this update we highlight updates and implications of the 2025 National Basic Medical Insurance Drug Catalog in China's ...